She concludes, “We need additional studies to give insight into the impact of things like cost of treatment, need for monitoring, and long-term effects of therapy—all of which are important considerations in the treatment of patients with uveitis.”
The study was funded by AbbVie, which markets adalimumab (Humira). Dr. Sheppard has received consulting fees from AbbVie and other companies. Three coauthors are AbbVie employees and own AbbVie stock, and another three have received consulting fees from AbbVie.
- Sheppard J, Joshi A, Betts KA, et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol. 2017 Apr 20. doi: 10.1001/jamaophthalmol.2017.0603. [Epub ahead of print]
- Burkholder BM, Ramulu PY. Improving more than just vision in noninfectious uveitis. JAMA Ophthalmol. 2017 Apr 20. doi: 10.1001/jamaophthalmol.2017.0716. [Epub ahead of print]